Trials that use: Non-inferiority trial design
New to this method? Read the tutorial →
60 results
- SURPASS-3Complete statistical analysis of SURPASS-3, a randomized phase 3 trial comparing tirzepatide with insulin degludec in participants with type 2 diabetes, including HbA1c, body weight, fasting serum glucose, treatment satisfaction, statistical methodology,…
- SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.
- SUSTAIN-3Independent statistical analysis of SUSTAIN-3, the randomized phase 3 trial comparing once-weekly semaglutide 1.0 mg with exenatide ER 2.0 mg in subjects with type 2 diabetes receiving 1–2 oral antidiabetic drugs.
- SUSTAIN-7Independent statistical analysis of the SUSTAIN-7 phase 3 trial comparing semaglutide with dulaglutide as add-on to metformin in subjects with type 2 diabetes, including mixed-effects modeling, non-inferiority and superiority testing, confidence intervals,…
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…
- SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…
- SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.
- TBTC Study 31Complete statistical analysis of TBTC Study 31, a randomized phase 3 trial of rifapentine-containing tuberculosis treatment-shortening regimens, including non-inferiority methodology, disease-free survival, safety, confidence intervals, and interpretation.
- TECOSComplete statistical analysis of TECOS, the randomized phase 3 study of sitagliptin versus placebo in type 2 diabetes mellitus, including non-inferiority analysis of MACE plus, Cox proportional-hazards methodology, secondary endpoints, safety, and…
- VADTIndependent statistical analysis of VADT (NCT00032487), evaluating intensive versus standard glycemic control in type 2 diabetes, with a focus on major macrovascular events, hazard ratios, log-rank testing, confidence intervals, and equivalence testing.